No-deal Brexit would stall the NHS medical revolution | Jeremy Farrar

Wellcome’s director offers a stark warning about the trust’s future in the UK

Every year, about 100 babies in the UK are diagnosed with rare, soft-tissue cancers. Treating young babies with chemotherapy and surgery is difficult and dangerous, but a new way of understanding these tumours using genomics offers hope. Researcher Sam Behjati devotes his work to decoding the DNA of rare childhood cancers. Recently, Behjati and his co-researchers revealed the genetic changes that cause a group of tumours to grow on babies’ kidneys. Now better targeted treatment using existing medicines is a possibility.

This week, the NHS becomes the first in the world to offer patients routine access to cutting-edge genomic medicine. This huge advance is in no small part because science in the UK has been at the forefront of the genomic revolution.

Continue reading...

from The Guardian https://ift.tt/2zGDpSf

No comments:

Post a Comment